As therapies have become more and more dependent on tumor as well as patient characteristics, obtaining tumor material has become of great importance. Liquid biopsies hold much potential as shown by a large amount of evidence across several studies. Clinical applications for circulating tumor cells (CTCs) are unfortunately still lacking. In part this is due to a lack of studies comparing liquid biopsies to conventional diagnostics and response measurements as well as studies showing that liquid biopsies can be used to switch therapies leading to improved outcomes. However, liquid biopsies using ctDNA for specific markers such as EGFR, ALK, ROS1 or RET have clinical applications because specific drugs are available.

中文翻译：

---

使用特别是 CTC 的液体活检在肺癌中的临床应用所需的证据

随着治疗越来越依赖于肿瘤和患者特征，获得肿瘤材料变得非常重要。多项研究的大量证据表明，液体活检具有很大的潜力。不幸的是，仍然缺乏循环肿瘤细胞（CTC）的临床应用。部分原因是缺乏将液体活检与传统诊断和反应测量进行比较的研究，以及表明液体活检可用于转换治疗以改善结果的研究。然而，使用 ctDNA 检测特定标志物（例如 EGFR、ALK、ROS1 或 RET）的液体活检具有临床应用，因为有特定药物可用。